Skip to main content

News and blog posts

24
Sep 2021

NHS is rolling out two types of testing (genetic testing for monogenic diabetes and placental growth factor (PLGF) testing to rule out pre-eclampsia)

In August 2021, NHS announced rolling out genetic testing for monogenic diabetes and placental growth factor (PLGF) testing to rule out pre-eclampsia. These decisions are made in line with the NHS Long Term Plan committed to increasing access to genomic testing, improving diabetes care across the country, and investing in cutting-edge technologies.
23
Sep 2021

MTRC is now an ISO 9001:2015 certified organization

In September 2021, MTRC received a certificate of conformity of the internal processes with the ISO 9001:2015 (quality management systems) standard. The certificate was issued by the United Kingdom Accreditation Service, UKAS. This confirms the commitment of the MTRC team to the provision of high-quality reimbursement services in Europe.
23
Sep 2021

Rapid HTAs of thirteen medical devices released in Tuscany

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 14763 of August 25, 2021, Tuscany Regional Healthcare has published assessments of thirteen medical devices of various therapeutic areas, including devices belonging to the obstetrics and gynecology field, as well as gastroenterology, urology, cardiovascular, endoscopy, spine, peripheral vascular, and other fields of care.
22
Sep 2021

Results of research for the assessment of medical innovations’ value at an early phase of development in the Netherlands

In August 2021, the Dutch Healthcare Institute (ZIN) published the results of research for the assessment of the value of medical innovations at an early phase of development. The Radboud university medical center was commissioned by the ZIN to investigate this question based on a case study for Anatomy Projector. The objective of the research was to answer the question of how the value of medical innovation is explored and expressed in an early phase, i.e., before market access.
21
Sep 2021

HTA for robot-assisted percutaneous coronary intervention in Norway 2021

In August 2021, the mini-HTA evaluation of the robot-assisted percutaneous coronary intervention was released. The method was described as safe and effective. After the introduction into the clinical practice, the method should be followed up for two years with a sufficient number of procedures to understand the real benefit. All procedures are to be registered in the Norwegian Registry for Invasive Cardiology.
20
Sep 2021

New experiments under Article 51 of the Social Security Financing Act in France

The French Ministry of Solidarity and Health constantly announces the new experiments initiated under Article 51 of the Social Security Financing Act. These experiments are focused on various topics concerning medical technologies and the organization of care. In the period from the end of July to the middle of September, new experiments related to cardiac rehabilitation, digital support for patients with cancer, and personalized perinatal support for women were announced.
17
Sep 2021

HTAs published by Finnish Coordinating Center for HTA in August 2021

In mid-August 2021, the Finnish Coordinating Center for Health Technology Assessment announced the release of the four accomplished rapid hospital assessments (HTA) performed by the Helsinki University Hospital. The accomplished rapid HTAs concern the cardiovascular, peripheral vascular, and endoscopy technology groups.
16
Sep 2021

Rapid HTA of PD-L1 assays in urothelial carcinoma published in Norway

On August 17, 2021, the National Institute of Public Health released a rapid HTA report on the evaluation of PD-L1 assays in urothelial carcinoma commissioned by the Ordering Forum. This assessment does not provide any conclusions on the effectiveness of various treatment strategies in the treatment of urothelial carcinoma in adults.
13
Sep 2021

Two methods received positive coverage decisions in Norway

On August 30, 2021, the Decision Forum for "New Methods" made a positive coverage decision for two methods: Transurethral Microwave Thermotherapy (TUMT) for benign prostatic hyperplasia treatment and organ donation using normothermic regional perfusion in patients with severe brain injury and who died of cardiac and respiratory arrest when life-prolonging treatment is discontinued.
10
Sep 2021

NHSX opens application submissions for Unified Tech Fund in England

On August 31, 2021, NHSX published a set of guidelines for digitized healthcare, including the Unified Tech Fund (UTF) prospectus, which seeks to simplify and consolidate the process for accessing technology funding. The UTF brings together several national technology funds. This amounts to £680 million available to NHS organizations throughout the financial year 2021 to 2022. The applications submission is open from August 31, 2021.